Distribution and outcomes of a phenotype-based approach to guide COPD management: Results from the CHAIN cohort

Cosio, B.G. ; Soriano, J.B. ; López-Campos, J.L. ; Calle, M. ; Soler, J.J. ; De-Torres, J. ; Marín, J.M. (Universidad de Zaragoza) ; Martínez, C. ; De Lucas, P. ; Mir, I. ; Peces-Barba, G. ; Feu-Collado, N. ; Solanes, I. ; Alfageme, I. ; Bonachera, J.C. ; Bautista, C.L. ; Domenech, A. ; Guzmán, R. ; Irigaray, R. ; Zamora, M.L. ; Ríos, A. ; Córdova, R. ; Viladrich, I.M. ; López, C.C. ; Acosta, A.S. ; González, J.A. ; Balbin, R.A. ; Balcells, E. ; Campos, E.M. ; Marin, A. ; Casanova, A.L. ; Moreno, A. ; Pérez, F.L.M. ; Miranda, J.A.R. ; Rodríguez, J.T. ; Gómez, R.G. ; De, Miguel D. ; Río, F.G. ; Lobato, S.D. ; Iturri, J.B.G. ; Royo, M.M. ; De, Diego Damia
Distribution and outcomes of a phenotype-based approach to guide COPD management: Results from the CHAIN cohort
Resumen: Rationale: The Spanish guideline for COPD (GesEPOC) recommends COPD treatment according to four clinical phenotypes: non-exacerbator phenotype with either chronic bronchitis or emphysema (NE), asthma-COPD overlap syndrome (ACOS), frequent exacerbator phenotype with emphysema (FEE) or frequent exacerbator phenotype with chronic bronchitis (FECB). However, little is known on the distribution and outcomes of the four suggested phenotypes. Objective: We aimed to determine the distribution of these COPD phenotypes, and their relation with one-year clinical outcomes. Methods: We followed a cohort of well-characterized patients with COPD up to one-year. Baseline characteristics, health status (CAT), BODE index, rate of exacerbations and mortality up to one year of follow-up were compared between the four phenotypes. Results: Overall, 831 stable COPD patients were evaluated. They were distributed as NE, 550 (66.2%); ACOS, 125 (15.0%); FEE, 38 (4.6%); and FECB, 99 (11.9%); additionally 19 (2.3%) COPD patients with frequent exacerbations did not fulfill the criteria for neither FEE nor FECB. At baseline, there were significant differences in symptoms, FEV1 and BODE index (all p<0.05). The FECB phenotype had the highest CAT score (17.1±8.2, p<0.05 compared to the other phenotypes). Frequent exacerbator groups (FEE and FECB) were receiving more pharmacological treatment at baseline, and also experienced more exacerbations the year after (all p<0.05) with no differences in one-year mortality. Most of NE (93%) and half of exacerbators were stable after one year. Conclusions: There is an uneven distribution of COPD phenotypes in stable COPD patients, with significant differences in demographics, patient-centered outcomes and health care resources use.
Idioma: Inglés
DOI: 10.1371/journal.pone.0160770
Año: 2016
Publicado en: PloS one 11, 9 (2016), 0160770 [15 pp]
ISSN: 1932-6203

Factor impacto JCR: 2.806 (2016)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 15 / 63 = 0.238 (2016) - Q1 - T1
Factor impacto SCIMAGO: 1.236 - Agricultural and Biological Sciences (miscellaneous) (Q1) - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2020-02-21-13:29:04)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2016-11-04, last modified 2020-02-21

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)